Compounds > fluoromisonidazole
Page last updated: 2024-08-26

fluoromisonidazole and Breast Cancer

fluoromisonidazole has been researched along with Breast Cancer in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Asano, A; Hasebe, T; Hirokawa, E; Kuji, I; Osaki, A; Saeki, T; Shimada, H; Sugitani, I; Takeuchi, H; Ueda, S; Yamane, T1
Sorace, AG; Syed, AK; Whisenant, JG; Woodall, R; Yankeelov, TE1
Bernards, N; Beynel, A; Boisgard, R; Bouet, S; Buvat, I; Kuhnast, B; Tavitian, B; Thézé, B1
Desco, M; Hernández-Agudo, E; Hidalgo, M; Lopez-Casas, PP; Megías, D; Mondejar, T; Mouron, S; Mulero, F; Quintela-Fandino, M; Sanchez, J; Soto-Montenegro, ML1
Cheng, J; Lei, L; Liu, G; Pan, L; Shao, Z; Sun, Y; Wang, X; Xu, J; Zhang, Y1

Other Studies

5 other study(ies) available for fluoromisonidazole and Breast Cancer

ArticleYear
Intracellular hypoxia measured by
    Breast cancer research : BCR, 2018, 07-27, Volume: 20, Issue:1

    Topics: Adult; Aged; Breast; Breast Neoplasms; Cell Hypoxia; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Misonidazole; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Receptors, Estrogen

2018
Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer.
    Neoplasia (New York, N.Y.), 2019, Volume: 21, Issue:1

    Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Diagnostic Imaging; Disease Models, Animal; Female; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Magnetic Resonance Imaging; Mice; Misonidazole; Positron-Emission Tomography; Receptor, ErbB-2; Reproducibility of Results; Trastuzumab; Xenograft Model Antitumor Assays

2019
Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
    BMC cancer, 2015, Jul-22, Volume: 15

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Misonidazole; Positron-Emission Tomography; Pyrroles; Sunitinib

2015
Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.
    Molecular oncology, 2016, Volume: 10, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Benzimidazoles; Breast; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Female; Fluorine Radioisotopes; Gemcitabine; Humans; Mice; Mice, Nude; Misonidazole; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Quinolones

2016
18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:3

    Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Ki-67 Antigen; Letrozole; Middle Aged; Misonidazole; Multimodal Imaging; Neoplasms, Hormone-Dependent; Nitriles; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Triazoles

2013